Table 1.
Clinical characteristics of MS patients analyzed for the migratory capacity of their peripheral blood T cells after methylprednisolone pulse therapy
| Age | Gender | Disease duration (years) | Immunomodulatory medication | Time since last GC pulse | |
|---|---|---|---|---|---|
| RRMS adult | |||||
| #1 | 29 | Male | 1 | Copaxone® | 10 months |
| #2 | 31 | Female | None | NA | NA |
| #3 | 33 | Female | 1 | Rebif® | 10 months |
| #4 | 36 | Male | 6 | Betaferon® | 6 months |
| PPMS adult | |||||
| #1 | 43 | Female | 10 | None | 3 years |
| #2 | 59 | Male | 10 | None | 3 months |
| #3 | 67 | Male | 2 | None | 10 weeks |
| RRMS children | |||||
| #1 | 11 | Female | 5 | None | 10 weeks |
| #2 | 15 | Female | 2 | Rebif® | 6 months |
| #3 | 17 | Female | 2 | Rebif® | 5 months |